Skip to content

Alliance of Infinity Trade

Artemether + Lumefantrine

Introducing AIT Pharmaceuticals Division’s Artemether + Lumefantrine Range

At AIT Pharmaceuticals Division, we are committed to providing innovative pharmaceutical solutions to combat infectious diseases worldwide. Our Artemether + Lumefantrine Range offers a potent combination therapy for the treatment of uncomplicated malaria caused by Plasmodium falciparum.

Category
Share

Drug Classification:

Artemether + Lumefantrine is classified as an antimalarial agent. It combines two active ingredients, Artemether and Lumefantrine, which work synergistically to eradicate malaria parasites from the body.

Formulations:

  • Artemether + Lumefantrine Dry Suspension:
    • Strength: Each 5ml of suspension contains 30 mg Artemether and 180 mg Lumefantrine.
    • Product Form: Dry suspension for oral administration.
    • Packing Specifications: Supplied in a bottle containing 60ml of suspension.
  • Artemether + Lumefantrine Tablets:
    • Strengths:
      • 20 mg Artemether + 120 mg Lumefantrine tablets (16’s)
      • 40 mg Artemether + 240 mg Lumefantrine tablets (8’s)
      • 80mg Artemether + 480mg Lumefantrine tablets (4’s)
    • Product Form: Oral tablets for convenient dosing.
    • Packing Specifications: Packaged in blister packs containing the specified number of tablets.

Indications:

Artemether + Lumefantrine is indicated for the treatment of uncomplicated malaria caused by Plasmodium falciparum, including multi-drug resistant strains. It is not recommended for prophylaxis or treatment of severe malaria.

Usage:

  • The oral suspension should be reconstituted according to the instructions provided before administration.
  • Tablets should be swallowed whole with water and may be taken with or without food.
  • Patients should complete the full course of treatment as prescribed by their healthcare provider, even if symptoms improve before completion.

Dosage:

  • Dosage regimens may vary based on factors such as the patient’s age, weight, and severity of infection.
  • The recommended dosage for Artemether + Lumefantrine is typically based on body weight and administered twice daily for three days.
  • The specific dosage for each strength of tablet or suspension should be determined by a qualified healthcare professional.

Pharmacokinetics:

  • Artemether is rapidly metabolized to its active metabolite dihydroartemisinin, which has a rapid onset of action against malaria parasites.
  • Lumefantrine is absorbed slowly and metabolized in the liver to its active metabolite desbutyl-lumefantrine, which contributes to the prolonged antimalarial activity.

Pharmacodynamics:

  • Artemether acts rapidly to kill malaria parasites, particularly the early stages of the parasite’s life cycle, including the ring and trophozoite stages.
  • Lumefantrine has a longer half-life and provides sustained antimalarial activity, preventing recrudescence of the infection and reducing the risk of treatment failure.

Side Effects:

  • Common side effects of Artemether + Lumefantrine may include nausea, vomiting, diarrhea, abdominal pain, and headache.
  • Rare but serious side effects may include cardiac arrhythmias, hypersensitivity reactions, and hepatic dysfunction.
  • Patients should be monitored for any adverse reactions during treatment, and healthcare providers should be informed of any concerning symptoms.

Experience the efficacy and reliability of AIT Pharmaceuticals Division’s Artemether + Lumefantrine Range in the fight against malaria. For more information, please contact us. We are dedicated to advancing global health through innovative pharmaceutical solutions.

Reviews

There are no reviews yet.

Be the first to review “Artemether + Lumefantrine”

Your email address will not be published. Required fields are marked *